Primate Monocytes - CD14, CD16 - Ziegler-Heitbrock


Recovery of systemic hyperinflammation in patients with severe SARS-CoV-2 infection.


INTRODUCTION: Patients with cardiovascular disease (CVD) and acute SARS-CoV-2 infection might show an altered immune response during COVID-19. MATERIAL AND METHODS: Twenty-three patients with CVD and SARS-CoV-2 infection were prospectively enrolled and received a cardiological assessment at study entry and during follow-up visit. Inclusion criteria of our study were age older than 18 years, presence of CVD, and acute SARS-CoV-2 infection. The median age of the patient cohort was 69 (IQR 55-79) years. 12 (52.2%) patients were men. Peripheral monocytes and chemokine/cytokine profiles were analysed. RESULTS: Numbers of classical and non-classical monocytes were significantly decreased during acute SARS-CoV-2 infection compared to 3-month recovery. While classical monocytes reached the expected level in peripheral blood after 3 months, the number of non-classical monocytes remained significantly reduced. DISCUSSION: All three monocyte subsets exhibited changes of established adhesion and activation markers. Interestingly, they also expressed higher levels of pro-inflammatory cytokines like macrophage migration inhibitory factor (MIF) at the time of recovery, although MIF was only slightly increased during the acute phase. CONCLUSION: Changes of monocyte phenotypes and increased MIF expression after 3-month recovery from acute SARS-CoV-2 infection may indicate persistent, possibly long-lasting, pro-inflammatory monocyte function in CVD patients.

Authors: Langnau C, Janing H, Kocaman H, Gekeler S, Günter M, Petersen-Uribe Á, Jaeger P, Koch B, Kreisselmeier KP, Castor T, Rath D, Gawaz MP, Autenrieth SE, Mueller KAL,
Journal: Biomarkers . 2023 Feb;28(1):97-110 doi:10.1080/1354750X.2022.2148745
Year: 2023
PubMed: PMID: 36377411 (Go to PubMed)